Incyte(US:INCY) Businesswire·2025-12-17 16:20Core Viewpoint - Incyte has received approval from the European Commission for Minjuvi® (tafasitamab) to treat relapsed or refractory follicular lymphoma, marking a significant advancement in the company's oncology portfolio [1] Group 1: Company Developments - The approval of Minjuvi® is a pivotal milestone for Incyte, enhancing its position in the oncology market [1] - This treatment option is specifically aimed at patients with relapsed or refractory follicular lymphoma, addressing an unmet medical need in this patient population [1] Group 2: Industry Impact - The approval is expected to contribute positively to the treatment landscape for follicular lymphoma, potentially improving patient outcomes [1] - This development may influence competitive dynamics within the oncology sector, as companies seek to address similar patient needs with innovative therapies [1]